rejuvant life tabs

Rejuvenate Biomed bags €3.2m for healthy aging R&D

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

Belgium biotech secures €3.2m Series A to advance the development of healthy aging products.

Rejuvenate Biomed, which is based in Antwerp, has announced it has completed a €3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).

Longevity.Technology: When we spoke to Rejuvenate’s CEO Dr Ann Beliën last year, addressing the challenges of aging was top of their agenda; with a USP of creating synergistic combination products that repurpose existing compounds but also bring an IP angle, with new runway Rejuvenate is going from strength to strength.

In tackling sarcopenia, a devastating and progressive loss of skeletal muscle mass and strength that strictly correlates with physical disability, poor quality of life and death, and for which the key risk factor is age, the company is addressing the need for therapy for this debilitating condition that is an enormous burden on individuals, as well as support systems and healthcare.

The Series A financing included lead investor Vesalius Biocapital III and private non-disclosed investors, as well as existing investors. Additionally, Rejuvenate acknowledges the ongoing support of Flanders Innovation and Entrepreneurship (VLAIO) in non-dilutive funding.

Speaking exclusively to Longevity.Technology, Dr Ann Beliën, PhD, Founder and CEO of Rejuvenate, said: “Increasing people’s healthspan by translating the science behind cell vitality and resilience into human therapeutics is the ultimate goal. This milestone is a major step in this direction and we are thankful for that!”

Elevant

Concurrent with the closing, the company has bolstered its scientific advisory board, which is now composed of Johan Auwerx, MD, PhD, Eric Verdin, MD, PhD, Marco Sandri, MD, PhD, Bart Braeckman, PhD, Björn Schumacher, PhD, and Andrea Maier, MD, PhD. Furthermore, a clinical advisory board has been established which is led by Jean-Yves Reginster, MD, PhD.

Rejuvenate’s lead candidate RJx-01 is a novel, safe, orally-administered, small molecule combination product being developed for sarcopenia, a debilitating condition defined by loss of muscle strength, quality and mass. The product was derived from an extensive in silico systems biology program, which mapped existing drugs with curated longevity pathways to create innovative, synergistic and highly effective combinations. RJx-01 has demonstrated strong preclinical evidence in multiple models and, with human safety data on hand for the individual compounds, the company plans to move the program into Phase Ib/IIb clinic trials later this year.

 


 

Increasing people’s healthspan by translating the science behind cell vitality and resilience into human therapeutics is the ultimate goal. This milestone is a major step in this direction and we are thankful for that!”

 


 

Dr Beliën added: “We are very pleased to welcome our lead investor Vesalius Biocapital III as well as the other new investors and wish to thank our existing shareholders for their continued support. Our team is highly driven to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. Using safe products as building blocks to develop innovative combinations such as RJx-01 has created unique opportunities in this field. Our dream of extending people’s health span is becoming a reality.”

Elevant

Vesalius Biocapital III is a specialist life sciences venture capital fund which targets later-stage European life science companies in drug development, medtech, diagnostics and digital health. Mr Stéphane Verdood, MBA, MSc, Managing Partner at Vesalius Biocapital III added: “Rejuvenate’s data show the potential for RJx-01 to drive our natural capacity to self-restore our cells. The company has a solid scientific and clinical basis coupled with a management team that is rapidly advancing RJx-01 for sarcopenia, and we are excited to be part of the next stage of the company’s growth.”

Images courtesy of Rejuvenate Biomed

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

New perspective in gerontology: epigenetic rejuvenation

Can biological age be set back by "making the clock tick backwards"? Scientists suggest that a partial phenotypic rejuvenation can be gained. Since the discovery...

Gerostate Alpha opens crowdfunded capital raise

Buck Institute-founded start-up Gerostate Alpha seeks to crowdfund its biotech platform. When Y Combinator so likes your ideas, it gives you $1 million to start...
Supps report ad middle